- Report
- October 2023
- 190 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- October 2023
- 189 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- June 2023
- 118 Pages
Global
From €4350EUR$4,500USD£3,739GBP
- Report
- July 2023
- 218 Pages
Global
From €4350EUR$4,500USD£3,739GBP
- Report
- October 2023
- 85 Pages
United States
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 30 Pages
United States
€2175EUR$2,250USD£1,870GBP
- Report
- July 2021
Global
From €917EUR$949USD£789GBP
- Report
- April 2024
Global
From €400EUR$443USD£356GBP
- Report
- March 2018
- 300 Pages
Global
From €2320EUR$2,400USD£1,994GBP
- Report
- July 2022
- 461 Pages
Global
From €4756EUR$5,092USD£3,950GBP
- Report
- October 2022
- 270 Pages
Global
From €3625EUR$3,750USD£3,116GBP
- Report
- September 2022
- 232 Pages
Global
From €3384EUR$3,500USD£2,908GBP
- Report
- August 2022
- 222 Pages
Global
From €3384EUR$3,500USD£2,908GBP
- Report
- February 2023
- 150 Pages
Global
From €5752EUR$5,950USD£4,944GBP
- Report
- February 2018
- 85 Pages
Global
From €5752EUR$5,950USD£4,944GBP
- Report
- April 2023
- 115 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- August 2022
- 111 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- June 2022
- 120 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- January 2022
- 122 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2658EUR$2,750USD£2,285GBP
Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms.
Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients.
Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more